OTCMKTS:SDZNY Sandoz Group (SDZNY) Stock Price, News & Analysis → Watch this FREE trading tutorial while it’s still available (From InvestorPlace) (Ad) Free SDZNY Stock Alerts $34.21 +0.26 (+0.77%) (As of 05/3/2024 05:47 PM ET) Add Compare Share Share Today's Range$33.83▼$34.4550-Day Range$27.81▼$34.2152-Week Range$25.71▼$34.94Volume38,818 shsAverage Volume188,630 shsMarket Capitalization$14.74 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Sandoz Group alerts: Email Address Sandoz Group MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish0.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth27.20%From $2.61 to $3.32 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Sandoz Group. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.51% of the outstanding shares of Sandoz Group have been sold short.Short Interest Ratio / Days to CoverSandoz Group has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Sandoz Group has recently increased by 1.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSandoz Group does not currently pay a dividend.Dividend GrowthSandoz Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SDZNY. Previous Next 1.9 News and Social Media Coverage News SentimentSandoz Group has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Sandoz Group this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SDZNY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sandoz Group insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.06% of the stock of Sandoz Group is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Sandoz Group are expected to grow by 27.20% in the coming year, from $2.61 to $3.32 per share.Price to Earnings Growth RatioSandoz Group has a PEG Ratio of 0.76. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSandoz Group has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Sandoz Group Stock (OTCMKTS:SDZNY)Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.Read More SDZNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SDZNY Stock News HeadlinesMay 2, 2024 | msn.comSandoz Group AG goes ex dividend tomorrowMay 2, 2024 | americanbankingnews.comSandoz Group (OTCMKTS:SDZNY) Trading 0.2% Higher May 4, 2024 | InvestorPlace (Ad)Watch this FREE trading tutorial while it’s still availableOn Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.April 30, 2024 | marketwatch.comSandoz Reaches Agreement With Amgen Resolving All Patent LitigationApril 30, 2024 | msn.comSandoz, Amgen reach agreement resolving patent litigation over biosimilarsApril 30, 2024 | globenewswire.comShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGApril 30, 2024 | reuters.comSandoz reaches agreement with Amgen over patent disputeApril 30, 2024 | globenewswire.comSandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsMay 4, 2024 | InvestorPlace (Ad)Watch this FREE trading tutorial while it’s still availableOn Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.April 29, 2024 | msn.comAmgen court hearing in patent lawsuit vs Sandoz over generic Prolia cancelledApril 22, 2024 | markets.businessinsider.comSandoz : Pyzchiva Approved In Europe For Gastroenterology, Dermatology, And Rheumatology TreatmentsApril 22, 2024 | globenewswire.comSandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringMarch 21, 2024 | globenewswire.comSandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesMarch 14, 2024 | msn.comSandoz Group Non-GAAP EPS of $2.20, revenue of $9.65B; initiates FY24 and long-term outlookMarch 13, 2024 | theglobeandmail.comThe Cultivated B Introduces n!Biomachines: Fit-For-Purpose Bioreactors Designed to Easily and Affordably Scale Cellular AgricultureMarch 13, 2024 | globenewswire.comSandoz reports fourth quarter 2023 sales and full-year 2023 resultsMarch 6, 2024 | finanznachrichten.deSandoz Group: Sandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | globenewswire.comSandoz receives FDA approval for first and only denosumab biosimilarsMarch 5, 2024 | finanznachrichten.deSandoz Group: Sandoz announces nominations to the Board of Directors and leadership changeMarch 5, 2024 | finance.yahoo.comSandoz announces nominations to the Board of Directors and leadership changeMarch 5, 2024 | globenewswire.comSandoz announces nominations to the Board of Directors and leadership changeMarch 4, 2024 | globenewswire.comSandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketFebruary 29, 2024 | msn.comGeneric/Biosimilar Player Sandoz Settles US Price Fixing Case For $265MFebruary 29, 2024 | finanznachrichten.deSandoz Group: Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsFebruary 29, 2024 | money.usnews.comSandoz Enters $265 Million Settlement Agreement in U.S. Price-Fixing CaseFebruary 29, 2024 | markets.businessinsider.comSandoz US Settles Antitrust Class Action Litigation With Direct Purchaser Class Plaintiffs February 29, 2024 | reuters.comSandoz enters $265 mln settlement agreement in U.S. price-fixing caseSee More Headlines Receive SDZNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sandoz Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:SDZNY CUSIPN/A CIKN/A Webwww.sandoz.com Phone41-61-324-11-11FaxN/AEmployees22,633Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio13.11 P/E Growth0.76Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.49 Current Ratio1.33 Quick Ratio0.86 Sales & Book Value Annual Sales$9.65 billion Price / Sales1.53 Cash Flow$2.23 per share Price / Cash Flow15.35 Book Value$20.08 per share Price / Book1.70Miscellaneous Outstanding Shares431,000,000Free FloatN/AMarket Cap$14.74 billion OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Richard Saynor (Age 57)Chief Executive Officer Mr. Colin Michael Bond (Age 64)Chief Financial Officer Mr. Asaf Gal (Age 55)Chief Technology Officer Ms. Claire D'Abreu-Hayling (Age 60)Chief Scientific Officer Ms. Karen M. KingHead Global Investor RelationsMs. Ingrid Sollerer (Age 50)General Counsel & Chief Compliance Officer Ms. Tripti Jha (Age 47)Chief People Officer Mr. Francisco Ballester (Age 63)President of International Mr. Pierre Bourdage (Age 45)Chief Commercial Officer Dr. Glenn A. Gerecke Ph.D. (Age 65)Chief Manufacturing & Supply Officer More ExecutivesKey CompetitorsShionogi & Co., Ltd.OTCMKTS:SGIOYEisaiOTCMKTS:ESALYEurofins ScientificOTCMKTS:ERFSFSysmexOTCMKTS:SSMXYSonic HealthcareOTCMKTS:SKHHYView All Competitors SDZNY Stock Analysis - Frequently Asked Questions Should I buy or sell Sandoz Group stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sandoz Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SDZNY shares. View SDZNY analyst ratings or view top-rated stocks. How have SDZNY shares performed in 2024? Sandoz Group's stock was trading at $32.01 at the start of the year. Since then, SDZNY stock has increased by 6.9% and is now trading at $34.21. View the best growth stocks for 2024 here. What ETFs hold Sandoz Group's stock? ETFs with the largest weight of Sandoz Group (OTCMKTS:SDZNY) stock in their portfolio include Franklin FTSE Switzerland ETF (FLSW).Horizon Kinetics Medical ETF (MEDX). How do I buy shares of Sandoz Group? Shares of SDZNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SDZNY) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sandoz Group AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
